
The top 100 biotech VCs - events.endpts.com
Every year Endpoints founding editor John Carroll and DealForma's Chris Dokomajilar identify the top 100 biotech VCs in operation based on the total amount invested in new rounds. This year, we’re bringing together a group of top experts in the field to discuss the key trends affecting one of the most consequential sources of money for biotech startups.
What’s on the horizon? The next era of alzheimer's treatments and ...
Over the last few years, we have seen the approval of the first disease-modifying therapies for Alzheimer’s disease, signifying a poignant turning point for the field. The next generation of therapeutics and diagnostics promises to define the future of treatments – based on the biology of aging approach – with
The top biotech megarounds of 2024 - endpts.com
Jan 2, 2025 · 2024 was the year of the private megaround. Nine-figure financings dominated biotech’s venture funding landscape, with 96 such rounds tallied by Endpoints News.The bevy …
Endpoints at #JPM25 - January 13-14, 2025 - San Francisco
In the biopharma world, the new year doesn’t start on January 1 — it starts when the industry descends on San Francisco for JPM. Dealmakers, investors, and corporate leaders will gather to chart the course for 2025 and take stock of the landscape, both financial and political.
Argenx reports Vyvgart sales streak, bolstered by launch in rare …
Oct 31, 2024 · Argenx’s Vyvgart has beat sales expectations for the eleventh quarter in a row, supported by strong uptake of a subcutaneous version of the drug in …
The Endpoints 100 survey: What are biopharma execs saying …
Dec 11, 2024 · We’ve asked our advisory group in the E100 about how things are shaping up at the FDA and HHS under the new Trump administration and what impact prospective changes could have on the drug development industry. Also, they have insights on the tense China-US relations and drug development, AI and our continuing focus on financing at …
Max Bayer - Endpoints News
reset password. We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours. email
Endpoints News – Biotech and pharma business news, with a focus …
An NIH cap on indirect cost payments for grant recipients is casting a shroud of uncertainty for research universities despite a judge’s order to block it.
Endpoints at JPM 2025: China, Trump 2.0, markets and more
Jan 10, 2025 · JPM agenda focuses on Trump 2.0 transition, market recovery & US-China dynamics, featuring talks with Sanofi's Ashrafian, ARCH's Nelsen, Scott Gottlieb & other leaders.
Apogee targets Dupixent head-to-head next year as it outlines …
Dec 2, 2024 · Apogee Therapeutics, an I&I biologics maker that quickly went public in 2023, said Monday it’s headed toward a Dupixent face-off next year as it looks …